NCT06788756 2026-04-13
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
Moleculin Biotech, Inc.
Phase 2/3 Recruiting
Moleculin Biotech, Inc.
Cancer Research Antwerp
Tianjin Medical University Cancer Institute and Hospital
Immunophotonics, Inc.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Bio-Thera Solutions
National Cancer Institute (NCI)
Guy's and St Thomas' NHS Foundation Trust
Beijing Friendship Hospital
Shanghai Miracogen Inc.
Zhongda Hospital
University of Zurich
FeRx